Skip to main content

OPHI · CollPlant Biotechnologies Ltd · Financials

Track OPHI — free
$3.65 At close · Nov 13 Q3 2024 earnings call transcript
Market Cap
$11.23M
Shares
3.08M
Volume · Nov 13 387.75K Avg daily vol (1 sessions) 387.75K

Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.

Diluted EPS
-$0.94 +35.2%
FY2025 Diluted EPS FY2019–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
$4.83M $5.63M $6M $6.74M $5.94M $4.67M $3.66M $3.72M
$912K $1.04M $1.1M $1.08M $773K $660K $539K $342K
— — — — — $34K $3.3M $2.18M
$380K $738K $788K $321K $219K — — —
-$6000 $642K $493K $172K $172K -$175K -$3.53M —
— $45.99M $59.99M — — — — —
— — — — — -$5.77M -$11.16M -$6.81M
USD/shares -$0.94 -$1.45 -$0.62 -$1.53 $0.02 -$0.84 -$2.23 —
USD/shares -$0.94 -$1.45 -$0.62 -$1.53 $0.02 -$0.84 -$2.23 —
shares 12.2M 11.45M 11.39M 11.03M 9.97M 6.89M 4.99M 4.38M
shares 12.2M 11.45M 11.39M 11.03M 11.97M 6.89M 4.99M 4.38M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Debt Profile

Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.

Read debt and covenant terms in your AI or your code through MCP and the API →

Reported debt balances

Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.

Reported balanceAs ofAmountSource
Current operating lease liabilities 2026-06-30 USD 894,000 6-K filed 2026-09-30
Noncurrent operating lease liabilities 2026-06-30 USD 1,766,000 6-K filed 2026-09-30
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.

Covenants

Covenant terms have not yet been verified for this profile.

The balance figures do not establish whether covenants apply or whether the company complies with them.

Loans, facilities and notes

The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
27.25×
Peer median 1.18×
EV/EBIT
—
Peer median 5.37×
P/E (TTM)
—
Peer median 4.69×
Price/Sales (TTM)
35.30×
Peer median 5.30×
Price/Book
3.81×
Peer median 1.05×

Peer medians compare against the 244 similar-size Biotechnology companies (of 593 listed).

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Geography (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
United States $2,176,000 $484,000 $10,839,000 $16,000 $14,951,000 $5,768,000 $2,078,000 $4,868,000
Europe and Other $98,000 — $28,000 $104,000 $633,000 — — —
Canada $96,000 — $87,000 $158,000 $57,000 — — —
Israel $1,000 $31,000 $5,000 $21,000 — — — —
Total — — — — — — — $5,014,000
Europe — — — — — $369,000 $240,000 —

By Product & Service (USD)

Component FY2025 FY2024 FY2023 FY2022 FY2021
Revenues from Milestones $2,000,000 — $10,000,000 — —
Revenues from Sales of Goods $371,000 $515,000 $959,000 $299,000 $1,595,000
Revenues From Licensing Agreement — — — — $14,000,000
Revenues From Rendering Of Services — — — — $46,000
Key facts CIK 1631487 13F (30d) 7 filings 7 filers Visit website Investor relations